A Phase III, open-label, multicenter, randomized study of Atezolizumab (Anti-PD-L1 anitbody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection
A Phase III, open-label, multicenter, randomized study of Atezolizumab (Anti-PD-L1 anitbody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.